British Association of Dermatologists' Guidelines for the Management of Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in Children and Young People, 2018

T. McPherson; L.S. Exton; S. Biswas; D. Creamer; P. Dziewulski; L. Newell; K.L. Tabor; G.N. Wali; G. Walker; R. Walker; S. Walker; A.E. Young; M.F. Mohd Mustapa; R. Murphy


The British Journal of Dermatology. 2019;181(1):37-54. 

In This Article

Purpose and Scope

The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the diagnosis and management of the full spectrum of Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS-TEN overlap in children (0–12 years) and young people (13–17 years) during the acute phase of the disease. The document aims to:

  • Offer an appraisal of all relevant literature up to July 2018, focusing on any key developments

  • Address important, practical clinical questions relating to the primary guideline objective

  • Provide guideline recommendations and, if appropriate, research recommendations

  • Discuss areas of uncertainty, potential developments and future directions.

These guidelines aim to provide recommendations on the diagnosis and management of paediatric SJS/TEN, to inform clinical decision making and, when justified by evidence, to standardize practice. There is currently widely divergent practice among different specialties and healthcare settings, and limited information on outcomes is available. This document should be sufficient to assist clinicians of all relevant specialties in the management of children (≤ 12 years old) and young people (< 18 years old) with SJS/TEN. The recommendations will also inform pathways of care to optimize healthcare delivery and highlight key areas of uncertainty for future research.

In this guideline, the term SJS/TEN encompasses the full spectrum of the disease, i.e. SJS, SJS-TEN overlap, and TEN. The guideline is presented as a detailed review with highlighted recommendations for practical use in primary care and in secondary care clinics, in addition to an updated Patient Information Leaflet (PIL) [available on the British Association of Dermatologists (BAD) website,].


The guideline does not cover adults (≥ 18 years old); a separate BAD guideline for the management of SJS/TEN in adults has been published.[1]